A Study for People with Metastatic Pancreatic Cancer KRAS G12D - DAWN-303

Overview

This explains the DAWN-303 study that is a global, randomized, double-blind, phase 3 study to evaluate the efficacy and safety of chemotherapy with or without INCB161734 (KRAS G12D inhibitor) in patients with metastatic pancreatic ductal adenocarcinoma

(ClinicalTrials.gov Identifier: NCT07522073).

Who can take part?  

You may be eligible for this study if you meet all of the following criteria:

• You have been diagnosed with pancreatic cancer that has spread to other parts of the body (metastatic) 
• Your tumor has been tested and has a KRAS G12D mutation
• You have not yet received treatment for metastatic disease (prior surgery or treatment before cancer spread may be acceptable)
• You are able to carry out most daily activities (ECOG performance status 0 or 1)
• Your cancer can be measured on imaging scans (measurable disease per RECIST 1.1)
• Your organs (such as your liver or kidneys) are functioning adequately based on lab tests

‍